G1 Therapeutics (GTHX) PT Lowered to $33 at Roth Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
G1 Therapeutics (GTHX) PT Lowered to $42 at Needham & Company
May 4, 2022 3:51 PM EDTNeedham & Company analyst Gil Blum lowered the price target on G1 Therapeutics (NASDAQ: GTHX) to $42.00 (from $44.00) while maintaining a Buy rating following earnings.
The analyst commented, "G1 reported COSELA sales of $5.5M, ~24% q/q increase. G1's internal sales team was... More
